UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK

Total Fees and Expenses Due:

	•	
In re:	:	Chapter 11

PURDUE PHARMA L.P., et al., : Case No. 19-23649 (RDD)

Debtors.¹ : (Jointly Administered)

SIXTH MONTHLY FEE STATEMENT OF KPMG LLP FOR COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF EXPENSES INCURRED AS TAX CONSULTANT FOR THE DEBTORS AND THE OFFICIAL COMMITTEE OF UNSECURED CREDITORS FOR THE PERIOD FROM JUNE 1, 2020 THROUGH JUNE 30, 2020

Name of Applicant:	KPMG LLP
Authorized to Provide Professional Services to:	The Debtors and the Official Committee of Unsecured Creditors
Date of Retention:	February 24, 2020, <i>nunc pro tunc</i> to December 23, 2019
Period for Which Compensation and Reimbursement is Sought:	June 1, 2020 through June 30, 2020
Amount of Compensation Sought as Actual, Reasonable, and Necessary:	\$ 204,044.40
Less 20% Holdback:	\$ (40,808.88)
Amount of Expense Reimbursement Sought as Actual, Reasonable, and Necessary:	\$ 0.00
	4 - 2 - 2 - 7 - 7

\$

163,235.52

The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF L.P. (0495), SVC Pharma L.P. (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Dated: August 5, 2020

/s/ Howard Steinberg

Howard Steinberg Partner, KPMG LLP 1350 Avenue of the Americas New York, New York 10019 (212) 872-6562

EXHIBIT A

Purdue Pharma L.P. Case No. 19-23649

Summary Of Hours and Discounted Fees Incurred By Professional June 1, 2020 through June 30, 2020

Professional Person	Position & Department	Country of Origin	Total Billed Hours	Ho	urly Billing Rate	Total Compensation		
Alan Zhao	Senior Manager - Tax	US	2.2	\$	695	\$	1,529.00	
Alejandro Merelles Rodriguez	Senior Associate - Tax	Luxembourg	6.8	\$	640	\$	4,352.00	
Aroen Rambhadjan	Partner - Tax	Netherlands	3.2	\$	884	\$	2,828.80	
Arpit Desai	Senior Manager - Tax	UK	0.4	\$	750	\$	300.00	
Ashley Armfield	Senior Associate - M&A Tax	US	16.3	\$	534	\$	8,704.20	
Becky Holtje	Senior Manager - Washington National Tax	US	40.3	\$	744	\$	29,983.20	
Bela Unell	Senior Manager - Washington National Tax	US	3.0	\$	744	\$	2,232.00	
Casey Nunez	Senior Manager - M&A Tax	US	21.5	\$	744	\$	15,996.00	
Danielle Moloughney	Associate - Tax	Canada	1.5	\$	172	\$	258.00	
Devon Rowles	Associate - M&A Tax	US	32.1	\$	350	\$	11,235.00	
Douglas Holland	Principal - Washington National Tax	US	2.8	\$	985	\$	2,758.00	
Emilien Lebas	Partner - Tax	Luxembourg	3.0	\$	985	\$	2,955.00	
Frankie Angeleri	Associate - Economic & Valuation Services	US	13.4	\$	520	\$	6,968.00	
Fred van Horzen	Partner - Tax	Netherlands	0.2	\$	884	\$	176.80	
Gavin Little	Managing Director - Tax	UK	0.4	\$	985	\$	394.00	
Gregory Bell	Partner - Tax	Canada	3.0	\$	743	\$	2,229.00	
Howard Steinberg	Partner - M&A Tax	US	1.8	\$	856	\$	1,540.80	
Isaac Hirsch	Managing Director - Int'l Tax	US	47.6	\$	819	\$	38,984.40	
Jess Commisso	Associate - M&A Tax	US	65.6	\$	350	\$	22,960.00	
Jonas Lau	Senior Manager - Tax	Canada	5.9	\$	614	\$	3,622.60	
Kieran Taylor	Senior Manager - Tax	US	6.7	\$	744	\$	4,984.80	
Lukas van der Veen	Manager - Tax	Netherlands	8.4	\$	565	\$	4,746.00	
Madeleine Latham	Associate - Tax	UK	0.4	\$	343	\$	137.20	
Mark Hoffenberg	Principal - Washington National Tax	US	2.6	\$	980	\$	2,548.00	
Molly Minnear	Principal - Economic & Valuation Services	US	1.7	\$	868	\$	1,475.60	
Monica Plangman	Associate Director - Bankruptcy	US	4.9	\$	264	\$	1,293.60	
Paul Harden	Managing Director - Tax	UK	3.4	\$	985	\$	3,349.00	
Pete DiMatteo	Manager - Int'l Tax	US	14.1	\$	650	\$	9,165.00	
Ray Bosques	Associate - M&A Tax	US	0.8	\$	350	\$	280.00	
Rob Keller	Managing Director - Washington National Tax	US	1.7	\$	893	\$	1,518.10	
Robin Lijzenga	Manager - Tax	Luxembourg	4.5	\$	730	\$	3,285.00	
Sam Tyler	Partner - Tax	Canada	2.3	\$	743	\$	1,708.90	
Sara Gonzalez Perez	Associate - Tax	Luxembourg	7.0	\$	380	\$	2,660.00	
Teresa Williams	Associate - Bankruptcy	US	6.3	\$	140	\$	882.00	
Tracy Stone	Principal - Washington National Tax	US	1.7	\$	906	\$	1,540.20	
Wendy Shaffer	Manager - Bankruptcy	US	22.1	\$	202	\$	4,464.20	
Subtotal of Hours and Discoun		O.S.	359.6	Ψ	202	<u>\$</u>	204,044.40	
	neu rees	:	339.0			Ф	•	
Total Discounted Fees						•	204,044.40	
Out of Pocket Expenses	Z					\$	204.044.46	
Total Fees and Out of Pocket I	-					\$	204,044.40	
Less Holdback Adjustment (20%						<u>ф</u>	(40,808.88)	
Net Requested Fees & Out of I	rocket expenses					\$	163,235.52	
Dlandad Handler Data				Ф.	567.42			

Blended Hourly Rate

\$

567.42

19-23649-shl Doc 1548 Filed 08/05/20 Entered 08/05/20 12:43:21 Main Document Pg 4 of 32

EXHIBIT B

Purdue Pharma L.P. Case No. 19-23649

Summary of Hours and Discounted Fees Incurred by Category June 1, 2020 through June 30, 2020

Category	Exhibit	Total Billed Hours	Total Fees Requested
Bankruptcy Tax Consulting Services	C1	326.3	\$ 197,404.60
Non -Working Travel Time	C2	0.0	\$ -
Retention Services	C3	0.0	\$ -
Fee Application Preparation Services	C4	33.3	\$ 6,639.80
Total		359.6	\$ 204,044.40

KPMG LLP Monthly Fee Statement Page 2 of 30

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Ashley Armfield	06/01/20	(0.6) Discussion between A. Armfield, J. Commisso, and D. Rowles (KPMG) to discuss updates and next steps related to the Purdue cash tax model as of 6/1/2020.	0.6	\$ 534	\$ 320.40
Devon Rowles	06/01/20	(0.6) Discussion between A. Armfield, J. Commisso, and D. Rowles (KPMG) to discuss updates and next steps related to the Purdue cash tax model as of 6/1/2020.	0.6	\$ 350	\$ 210.00
Jess Commisso	06/01/20	(0.6) Discussion between A. Armfield, J. Commisso, and D. Rowles (KPMG) to discuss updates and next steps related to the Purdue cash tax model as of 6/1/2020.	0.6	\$ 350	\$ 210.00
Molly Minnear	06/01/20	(0.6) Review of certain documents in order to prepare for upcoming discussion with KPMG project team.	0.6	\$ 868	\$ 520.80
Danielle Moloughney	06/01/20	(0.6) Associate level review (from Canadian tax perspective) of slide deck sent by KPMG US with regards to a potential disposition.	0.6	\$ 172	\$ 103.20
Bela Unell	06/01/20	Conference call with B. Unell - partial attendance, I. Hirsch, C. Nunez, R. Holtje and P. DiMatteo (KPMG) to discuss and refine research regarding potential tax deductions.	0.5	\$ 744	\$ 372.00
Becky Holtje	06/01/20	Conference call with B. Unell - partial attendance, I. Hirsch, C. Nunez, R. Holtje and P. DiMatteo (KPMG) to discuss and refine research regarding potential tax deductions.	0.6	\$ 744	\$ 446.40
Casey Nunez	06/01/20	Conference call with B. Unell - partial attendance, I. Hirsch, C. Nunez, R. Holtje and P. DiMatteo (KPMG) to discuss and refine research regarding potential tax deductions.	0.6	\$ 744	\$ 446.40
Isaac Hirsch	06/01/20	Conference call with B. Unell - partial attendance, I. Hirsch, C. Nunez, R. Holtje and P. DiMatteo (KPMG) to discuss and refine research regarding potential tax deductions.	0.6	\$ 819	\$ 491.40
Pete DiMatteo	06/01/20	Conference call with B. Unell - partial attendance, I. Hirsch, C. Nunez, R. Holtje and P. DiMatteo (KPMG) to discuss and refine research regarding potential tax deductions.	0.6	\$ 650	\$ 390.00
Ashley Armfield	06/01/20	(0.8) Discussion between A. Armfield and D. Rowles (KPMG) to discuss effective tax rate by Mundipharma entity pursuant to creating sensitivity analysis for the Purdue cash tax model	0.8	\$ 534	\$ 427.20
Devon Rowles	06/01/20	(0.8) Discussion between A. Armfield and D. Rowles (KPMG) to discuss effective tax rate by Mundipharma entity pursuant to creating sensitivity analysis for the Purdue cash tax model	0.8	\$ 350	\$ 280.00
Ashley Armfield	06/01/20	(0.8) Discussion with I. Hirsch, A. Armfield and J. Commisso (KPMG) regarding the allocation alternatives and sensitivity analysis updates within the cash tax model as of 6/1/2020.	0.8	\$ 534	\$ 427.20

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Isaac Hirsch	06/01/20	(0.8) Discussion with I. Hirsch, A. Armfield and J. Commisso (KPMG) regarding the allocation alternatives and sensitivity analysis updates within the cash tax model as of 6/1/2020.	0.8	\$ 819	\$ 655.20
Jess Commisso	06/01/20	(0.8) Discussion with I. Hirsch, A. Armfield and J. Commisso (KPMG) regarding the allocation alternatives and sensitivity analysis updates within the cash tax model as of 6/1/2020.	0.8	\$ 350	\$ 280.00
Isaac Hirsch	06/01/20	(1.1) Performed Managing Director review of latest round of updates to sensitivity analysis for cash tax model.	1.1	\$ 819	\$ 900.90
Devon Rowles	06/01/20	(1.1) Updates to assigned portion of Purdue cash tax model based on results of discussion with A. Armfield (KPMG Senior Associate).	1.1	\$ 350	\$ 385.00
Kieran Taylor	06/01/20	, , , , , , , , , , , , , , , , , , ,	1.4	\$ 744	\$ 1,041.60
Jess Commisso	06/01/20	(2.2) Continued, on same day, to update the Purdue cash tax model pursuant to changes in value allocation.	2.2	\$ 350	\$ 770.00
Becky Holtje	06/01/20	(2.8) Performed research to facilitate cash tax modeling, relating to certain potential deductions	2.8	\$ 744	\$ 2,083.20
Jess Commisso	06/01/20	(3.9) Updates to the Purdue cash tax model pursuant to changes in value allocation.	3.9	\$ 350	\$ 1,365.00
Ashley Armfield	06/02/20	Conference call between I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield (KPMG US), P. Harden, G. Little, A. Desai, and M. Latham (KPMG UK) to discuss structuring and United Kingdom tax considerations associated with the contemplated disposition of various Mundipharma entities.	0.4	\$ 534	\$ 213.60
Casey Nunez	06/02/20	Conference call between I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield (KPMG US), P. Harden, G. Little, A. Desai, and M. Latham (KPMG UK) to discuss structuring and United Kingdom tax considerations associated with the contemplated disposition of various Mundipharma entities.	0.4	\$ 744	\$ 297.60
Gavin Little	06/02/20	Conference call between I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield (KPMG US), P. Harden, G. Little, A. Desai, and M. Latham (KPMG UK) to discuss structuring and United Kingdom tax considerations associated with the contemplated disposition of various Mundipharma entities.	0.4	\$ 985	\$ 394.00
Isaac Hirsch	06/02/20	Conference call between I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield (KPMG US), P. Harden, G. Little, A. Desai, and M. Latham (KPMG UK) to discuss structuring and United Kingdom tax considerations associated with the contemplated disposition of various Mundipharma entities.	0.4	\$ 819	\$ 327.60

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	 Amount
Pete DiMatteo	06/02/20	Conference call between I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield (KPMG US), P. Harden, G. Little, A. Desai, and M. Latham (KPMG UK) to discuss structuring and United Kingdom tax considerations associated with the contemplated disposition of various Mundipharma entities.	0.4	\$ 650	\$ 260.00
Arpit Desai	06/02/20	Conference call between I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield, P. Harden, G. Little, A. Desai, and M. Latham (KPMG) to discuss structuring and United Kingdom tax considerations associated with the contemplated disposition of various Mundipharma entities.	0.4	\$ 750	\$ 300.00
Madeleine Latham	06/02/20	Conference call between I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield, P. Harden, G. Little, A. Desai, and M. Latham (KPMG) to discuss structuring and United Kingdom tax considerations associated with the contemplated disposition of various Mundipharma entities.	0.4	\$ 343	\$ 137.20
Paul Harden	06/02/20	Conference call between I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield, P. Harden, G. Little, A. Desai, and M. Latham (KPMG) to discuss structuring and United Kingdom tax considerations associated with the contemplated disposition of various Mundipharma entities.	0.4	\$ 985	\$ 394.00
Danielle Moloughney	06/02/20	Continued (from previous day) associate level review (from Canadian tax perspective) of slide deck sent by KPMG US with regards to a potential disposition.	0.4	\$ 172	\$ 68.80
Frankie Angeleri	06/02/20	(0.5) Meeting with M. Minnear, K. Taylor and F. Angeleri (KPMG) to discuss transfer pricing materials we have received to date and next steps related to analysis as of 6/2/2020.	0.5	\$ 520	\$ 260.00
Kieran Taylor	06/02/20	(0.5) Meeting with M. Minnear, K. Taylor and F. Angeleri (KPMG) to discuss transfer pricing materials we have received to date and next steps related to analysis as of 6/2/2020.	0.5	\$ 744	\$ 372.00
Molly Minnear	06/02/20	(0.5) Meeting with M. Minnear, K. Taylor and F. Angeleri (KPMG) to discuss transfer pricing materials we have received to date and next steps related to analysis as of 6/2/2020.	0.5	\$ 868	\$ 434.00
Alan Zhao	06/02/20	(0.5) Updated PowerBI dashboard template to include additional calculation measures / formulas to show sensitivity results from Purdue cash tax model.	0.5	\$ 695	\$ 347.50
Jess Commisso	06/02/20	(0.8) Discussion with R. Bosques and J. Commisso (KPMG) regarding creation of PowerBI charts pursuant to displaying comparison of various disposition scenarios of Mundipharma entities.	0.8	\$ 350	\$ 280.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Ray Bosques	06/02/20	(0.8) Discussion with R. Bosques and J. Commisso (KPMG) regarding creation of PowerBI charts pursuant to displaying comparison of various disposition scenarios of Mundipharma entities.	0.8	\$ 350	\$ 280.00
Aroen Rambhadjan	06/02/20	(1.2) Netherlands Partner review of comments for deck describing alternative scenario on disposition of Dutch Entity initially prepared by L. van der Veen (KPMG Netherlands).	1.2	\$ 884	\$ 1,060.80
Devon Rowles	06/02/20	(1.3) Reviewed the virtual data room for tax relevant information received as of 6/5/2020 in order to notify the broader KPMG US team about tax relevant documents received.	1.3	\$ 350	\$ 455.00
Ashley Armfield	06/02/20	(1.3) Senior Associate review of sensitivity analysis prepared relating to the cash tax model, with regards to various valuations and the impact on cash taxes, pursuant to providing to investment bankers / legal counsel representing the debtor as well as the unsecured creditors committee	1.3	\$ 534	\$ 694.20
Jess Commisso	06/02/20	(1.4) Continued (same day) to update the Purdue cash tax model pursuant to changes to sensitivity analysis / removal of disposition entity.	1.4	\$ 350	\$ 490.00
Kieran Taylor	06/02/20	(1.4) Analysis of certain Mundipharma relationships from a Transfer Pricing perspective.	1.4	\$ 744	\$ 1,041.60
Jonas Lau	06/02/20	Prepared potential Canadian tax comments for slide deck prepared by KPMG US regarding potential dispositions	1.5	\$ 614	\$ 921.00
Becky Holtje	06/02/20	(1.7) Perform research, as of 6/2/2020, to facilitate cash tax modeling, relating to certain potential deductions	1.7	\$ 744	\$ 1,264.80
Lukas van der Veen	06/02/20	Draft comments for deck describing alternative scenario on disposition of Netherlands Mundipharma entity via a proposed disposition in preparation to send to P. DiMatteo (KPMG US).	3.1	\$ 565	\$ 1,751.50
Jess Commisso	06/02/20	(3.9) Creation of PowerBI visual charts to display sensitivity analysis scenarios and global cash tax liability / net proceeds following disposition of Mundipharma entities.	3.9	\$ 350	\$ 1,365.00
Jess Commisso	06/02/20	(3.9) Updates to designated portion of the cash tax model, as of 6/2/2020, pursuant to changes to sensitivity analysis / removal of disposition entity.	3.9	\$ 350	\$ 1,365.00
Lukas van der Veen	06/03/20	Review e-mail communication with I. Hirsch (KPMG US) on potential disposition of a Netherlands Mundipharma entity.	0.2	\$ 565	\$ 113.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Alan Zhao	06/03/20	(0.5) Updated PowerBI dashboard template for M&A Tax Team C. Nunez and A. Armfield (KPMG) by adding conditional column within the PowerBI queries to produce meaningful visuals in connection with the Purdue cash tax model.	0.5	\$ 695	\$ 347.50
Casey Nunez	06/03/20	(0.8) Performed M&A Tax Senior Manager review of updates to information request list as of 6/3/2020.	0.8	\$ 744	\$ 595.20
Devon Rowles	06/03/20	(1.1) Updates to assigned portion of Purdue cash tax model with regards to review comments received from A. Armfield (KPMG Senior Associate) as of 6/3/2020.	1.1	\$ 350	\$ 385.00
Jess Commisso	06/03/20	Continued (same day) to perform updates to designated portion of Purdue cash tax model per review comments received from A. Armfield (KPMG Senior Associate) as of 6/3/2020.	1.2	\$ 350	\$ 420.00
Sam Tyler	06/03/20	Perform International Canadian Partner review of slide deck with regards to a contemplated disposition of a Canadian entity	1.3	\$ 743	\$ 965.90
Gregory Bell	06/03/20	Perform Domestic Canadian Partner review of slide deck with regards to a contemplated disposition of a Canadian entity	2.0	\$ 743	\$ 1,486.00
Becky Holtje	06/03/20	(3.2) Performed research, as of 6/3/2020, to facilitate cash tax modeling, relating to certain potential deductions	3.2	\$ 744	\$ 2,380.80
Isaac Hirsch	06/03/20	(1.3) Managing Director review of updated sensitivity analysis for global cash tax model; (1.8) Analysis of availability of potential tax deduction for certain payments; (0.8) Managing Director review of advice from Netherlands tax specialist regarding treaty application for potential sale	3.9	\$ 819	\$ 3,194.10
Jess Commisso	06/03/20	(3.9) Updates to the PowerBI visuals per review comments received from A. Armfield (KPMG Senior Associate) as of 6/3/2020.	3.9	\$ 350	\$ 1,365.00
Jess Commisso	06/03/20	(3.9) Updates to designated portion of the Purdue cash tax model per review comments received from A. Armfield (KPMG Senior Associate) as of 6/3/2020.	3.9	\$ 350	\$ 1,365.00
Alan Zhao	06/04/20	(0.5) Updated PowerBI dashboard template with regards to requests from M&A Tax Team (C. Nunez and A. Armfield) as of $6/4/2020$.	0.5	\$ 695	\$ 347.50
Devon Rowles	06/04/20	(0.7) Updated assigned portion of Purdue cash tax model with regards to review comments received from KPMG senior associate (A. Armfield) specifically related to the Power BI charts for sensitivity analysis	0.7	\$ 350	\$ 245.00

19-23649-shl Doc 1548 Filed 08/05/20 Entered 08/05/20 12:43:21 Main Document Pg 10 of 32

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Bela Unell	06/04/20	Conference call with T. Stone, B. Unell - partial attendance, R. Keller, I. Hirsch, C. Nunez, R. Holtje and P. DiMatteo (KPMG) to further discuss and refine research regarding potential tax deductions.	0.7	\$ 744	\$ 520.80
Becky Holtje	06/04/20	Conference call with T. Stone, B. Unell - partial attendance, R. Keller, I. Hirsch, C. Nunez, R. Holtje and P. DiMatteo (KPMG) to further discuss and refine research regarding potential tax deductions.	0.9	\$ 744	\$ 669.60
Casey Nunez	06/04/20	Conference call with T. Stone, B. Unell - partial attendance, R. Keller, I. Hirsch, C. Nunez, R. Holtje and P. DiMatteo (KPMG) to further discuss and refine research regarding potential tax deductions.	0.9	\$ 744	\$ 669.60
Isaac Hirsch	06/04/20	Conference call with T. Stone, B. Unell - partial attendance, R. Keller, I. Hirsch, C. Nunez, R. Holtje and P. DiMatteo (KPMG) to further discuss and refine research regarding potential tax deductions.	0.9	\$ 819	\$ 737.10
Pete DiMatteo	06/04/20	Conference call with T. Stone, B. Unell - partial attendance, R. Keller, I. Hirsch, C. Nunez, R. Holtje and P. DiMatteo (KPMG) to further discuss and refine research regarding potential tax deductions.	0.9	\$ 650	\$ 585.00
Rob Keller	06/04/20	Conference call with T. Stone, B. Unell - partial attendance, R. Keller, I. Hirsch, C. Nunez, R. Holtje and P. DiMatteo (KPMG) to further discuss and refine research regarding potential tax deductions.	0.9	\$ 893	\$ 803.70
Tracy Stone	06/04/20	Conference call with T. Stone, B. Unell - partial attendance, R. Keller, I. Hirsch, C. Nunez, R. Holtje and P. DiMatteo (KPMG) to further discuss and refine research regarding potential tax deductions.	0.9	\$ 906	\$ 815.40
Becky Holtje	06/04/20	(1.2) Perform research, as of 6/4/2020, to facilitate cash tax modeling, relating to certain potential deductions	1.2	\$ 744	\$ 892.80
Jonas Lau	06/04/20	Updated Canadian tax comments (per request of KPMG US) in slide deck prepared by KPMG US related to potential disposition alternative for a Canadian entity.	1.5	\$ 614	\$ 921.00
Kieran Taylor	06/04/20	(1.6) Performed analysis of transfer pricing summary as prepared by EY - with focus on background as to the existing transfer pricing framework of Purdue.	1.6	\$ 744	\$ 1,190.40
Isaac Hirsch	06/04/20	(1.4) Managing Director review of updated sensitivity analysis for global cash tax model as of 6/4/2020; (0.4) Managing Director review of information request lists for updates to cash tax model and analysis of potential NOL carryback.	1.8	\$ 819	\$ 1,474.20
Ashley Armfield	06/04/20	(2.1) Drafted review comments related to cash tax model updates / presentation for upcoming Purdue banker call.	2.1	\$ 534	\$ 1,121.40

19-23649-shl Doc 1548 Filed 08/05/20 Entered 08/05/20 12:43:21 Main Document Pg 11 of 32

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Lukas van der Veen	06/04/20	Draft comments for deck describing alternative scenario on disposition of Netherlands Mundipharma entity in preparation to send to I. Hirsch (KPMG US).	2.4	\$ 565	\$ 1,356.00
Jess Commisso	06/04/20	(3.9) Updated the PowerBI visuals per review comments received from A. Armfield (KPMG Senior Associate) as of 6/4/2020.	3.9	\$ 350	\$ 1,365.00
Ashley Armfield	06/05/20	(0.6) Drafting assumptions to include in new deliverable for sensitivity analysis surrounding the cash tax model.	0.6	\$ 534	\$ 320.40
Alan Zhao	06/05/20	(0.7) Updated PowerBI dashboard template for M&A Tax Team C. Nunez and A. Armfield (KPMG) to bring in Alternate value allocation tab data from Purdue Cash Tax model.	0.7	\$ 695	\$ 486.50
Becky Holtje	06/05/20	(1.2) Perform research, as of 6/5/2020, to facilitate cash tax modeling, relating to certain potential deductions	1.2	\$ 744	\$ 892.80
Isaac Hirsch	06/05/20	(1.2) Perform Managing Director review of sensitivity analysis, as of 6/5/2020, with respect to cash tax analysis.	1.2	\$ 819	\$ 982.80
Jess Commisso	06/05/20	(2.2) Continued (from earlier in the day) to update the PowerBI visuals per review comments received from I. Hirsch (KPMG Managing Director) as of 6/5/2020.	2.2	\$ 350	\$ 770.00
Casey Nunez	06/05/20	(2.2) Performed M&A Tax Senior Manager review of valuation sensitivity analysis deliverable as of 6/5/2020.	2.2	\$ 744	\$ 1,636.80
Jess Commisso	06/05/20	(3.9) Updates to the PowerBI visuals per review comments received from I. Hirsch (KPMG Managing Director) as of 6/5/2020.	3.9	\$ 350	\$ 1,365.00
Becky Holtje	06/08/20	(0.1) Continued, same day, to perform research to facilitate cash tax modeling, relating to certain potential deductions	0.1	\$ 744	\$ 74.40
Lukas van der Veen	06/08/20	(0.4) Finalize comments included in deck on the alternative disposition of a dutch entity following review by A. Rambhadjan (KPMG Netherlands). Slide deck has been shared with KPMG US on June 8, 2020.	0.4	\$ 565	\$ 226.00
Sam Tyler	06/08/20	Performed International Canadian Partner review of final version of slide deck related to contemplated disposition of a Canadian entity - prior to providing to KPMG US.	0.5	\$ 743	\$ 371.50
Gregory Bell	06/08/20	Performed Domestic Canadian Partner review of final version of slide deck prepared by KPMG Canada staff related to contemplated disposition of a Canadian entity	0.5	\$ 743	\$ 371.50
Danielle Moloughney	06/08/20	Conference call with (S. Tyler, G. Bell, J. Lau and D. Moloughney) (all KPMG Canada) project team to discuss planning idea for the contemplated disposition of a Canadian entity.	0.5	\$ 172	\$ 86.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Gregory Bell	06/08/20	Conference call with (S. Tyler, G. Bell, J. Lau and D. Moloughney) (all KPMG Canada) project team to discuss planning idea for the contemplated disposition of a Canadian entity.	0.5	\$ 743	\$ 371.50
Jonas Lau	06/08/20	Conference call with (S. Tyler, G. Bell, J. Lau and D. Moloughney) (all KPMG Canada) project team to discuss planning idea for the contemplated disposition of a Canadian entity.	0.5	\$ 614	\$ 307.00
Sam Tyler	06/08/20	Conference call with (S. Tyler, G. Bell, J. Lau and D. Moloughney) (all KPMG Canada) project team to discuss planning idea for the contemplated disposition of a Canadian entity.	0.5	\$ 743	\$ 371.50
Pete DiMatteo	06/08/20	(0.6) Review proposed settlement term sheet to identify potential claims for purposes of correspondence with T. Stone (KPMG)	0.6	\$ 650	\$ 390.00
Casey Nunez	06/08/20	(0.7) Continued to perform M&A Tax Senior Manager review of updated valuation sensitivity analysis deliverable	0.7	\$ 744	\$ 520.80
Rob Keller	06/08/20	(0.8) Conference call with T. Stone and R. Keller (KPMG) to further discuss and refine research regarding potential tax deductions.	0.8	\$ 893	\$ 714.40
Tracy Stone	06/08/20	(0.8) Conference call with T. Stone and R. Keller (KPMG) to further discuss and refine research regarding potential tax deductions.	0.8	\$ 906	\$ 724.80
Aroen Rambhadjan	06/08/20	(0.9) Partner review comments (initially prepared by L. van der Veen -KPMG Netherlands tax specialist) included in deck on the alternative disposition of Dutch entity.	0.9	\$ 884	\$ 795.60
Jonas Lau	06/08/20	(1.1) Finalized slide deck regarding planning alternatives and (0.4) drafted responses to questions from KPMG US related to same	1.5	\$ 614	\$ 921.00
Devon Rowles	06/08/20	(1.8) Updates to Purdue cash tax model per KPMG Managing Director (I. Hirsch) review comments, specifically with respect to the Power BI charts for sensitivity analysis	1.8	\$ 350	\$ 630.00
Isaac Hirsch	06/08/20	(0.8) Finalize information request list to send Norton Rose for purposes of refining global cash tax model; (1.3) Managing Director review of valuation sensitivity analysis for cash tax model as of 6/8/2020; (0.4) Managing Director review of correspondence with KPMG Washington National Tax regarding potential deductions.	2.5	\$ 819	\$ 2,047.50
Devon Rowles	06/08/20	(3.1) Updated assigned portion of Purdue cash tax model per KPMG senior associate (A. Armfield) review comments, specifically with respect to the Power BI charts for sensitivity analysis	3.1	\$ 350	\$ 1,085.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Becky Holtje	06/08/20	(3.9) Perform research, as of 6/8/2020, to facilitate cash tax modeling, relating to certain potential deductions	3.9	\$ 744	\$ 2,901.60
Jess Commisso	06/08/20	(3.9) Updates to the PowerBI visuals per review comments received from I. Hirsch (KPMG Managing Director) as of 6/8/2020.	3.9	\$ 350	\$ 1,365.00
Becky Holtje	06/09/20	(0.7) Continued, same day, to perform research to facilitate cash tax modeling, relating to certain potential deductions	0.7	\$ 744	\$ 520.80
Pete DiMatteo	06/09/20	Performed international tax manager preparation of PowerPoint slides depicting proposed planning related to contemplated Canadian (2.2) and Dutch (1.2) dispositions.	3.4	\$ 650	\$ 2,210.00
Becky Holtje	06/09/20	(3.9) Perform research, as of 6/9/2020, to facilitate cash tax modeling, relating to certain potential deductions	3.9	\$ 744	\$ 2,901.60
Ashley Armfield	06/10/20	(0.8) Discussion with H. Steinberg, M. Hoffenberg, D. Holland, B. Unell, C. Nunez, I. Hirsch, P. DiMatteo, A. Armfield, and J. Commisso (KPMG) regarding review of client deliverable of sensitivity analysis charts and additional information requests.	0.8	\$ 534	\$ 427.20
Bela Unell	06/10/20	(0.8) Discussion with H. Steinberg, M. Hoffenberg, D. Holland, B. Unell, C. Nunez, I. Hirsch, P. DiMatteo, A. Armfield, and J. Commisso (KPMG) regarding review of client deliverable of sensitivity analysis charts and additional information requests.	0.8	\$ 744	\$ 595.20
Casey Nunez	06/10/20	(0.8) Discussion with H. Steinberg, M. Hoffenberg, D. Holland, B. Unell, C. Nunez, I. Hirsch, P. DiMatteo, A. Armfield, and J. Commisso (KPMG) regarding review of client deliverable of sensitivity analysis charts and additional information requests.	0.8	\$ 744	\$ 595.20
Douglas Holland	06/10/20	(0.8) Discussion with H. Steinberg, M. Hoffenberg, D. Holland, B. Unell, C. Nunez, I. Hirsch, P. DiMatteo, A. Armfield, and J. Commisso (KPMG) regarding review of client deliverable of sensitivity analysis charts and additional information requests.	0.8	\$ 985	\$ 788.00
Howard Steinberg	06/10/20	(0.8) Discussion with H. Steinberg, M. Hoffenberg, D. Holland, B. Unell, C. Nunez, I. Hirsch, P. DiMatteo, A. Armfield, and J. Commisso (KPMG) regarding review of client deliverable of sensitivity analysis charts and additional information requests.	0.8	\$ 856	\$ 684.80
Isaac Hirsch	06/10/20	(0.8) Discussion with H. Steinberg, M. Hoffenberg, D. Holland, B. Unell, C. Nunez, I. Hirsch, P. DiMatteo, A. Armfield, and J. Commisso (KPMG) regarding review of client deliverable of sensitivity analysis charts and additional information requests.	0.8	\$ 819	\$ 655.20

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Jess Commisso	06/10/20	(0.8) Discussion with H. Steinberg, M. Hoffenberg, D. Holland, B. Unell, C. Nunez, I. Hirsch, P. DiMatteo, A. Armfield, and J. Commisso (KPMG) regarding review of client deliverable of sensitivity analysis charts and additional information requests.	0.8	\$ 350	\$ 280.00
Mark Hoffenberg	06/10/20	(0.8) Discussion with H. Steinberg, M. Hoffenberg, D. Holland, B. Unell, C. Nunez, I. Hirsch, P. DiMatteo, A. Armfield, and J. Commisso (KPMG) regarding review of client deliverable of sensitivity analysis charts and additional information requests.	0.8	\$ 980	\$ 784.00
Pete DiMatteo	06/10/20	(0.8) Discussion with H. Steinberg, M. Hoffenberg, D. Holland, B. Unell, C. Nunez, I. Hirsch, P. DiMatteo, A. Armfield, and J. Commisso (KPMG) regarding review of client deliverable of sensitivity analysis charts and additional information requests.	0.8	\$ 650	\$ 520.00
Casey Nunez	06/10/20	(1.1) Performed M&A Tax Senior Manager review of cash tax model updates for valuation sensitivity analysis.	1.1	\$ 744	\$ 818.40
Becky Holtje	06/10/20	(1.6) Perform research, as of 6/10/2020, to facilitate cash tax modeling relating to timing of certain deductions	1.6	\$ 744	\$ 1,190.40
Isaac Hirsch	06/10/20	(1.8) Perform Managing Director review of sensitivity analysis regarding allocation of proceeds between various entities, in preparation for external call with Purdue and UCC legal and financial counsel	1.8	\$ 819	\$ 1,474.20
Ashley Armfield	06/10/20	(2.1) Updating presentation relating to providing external advisors with cash tax sensitivity analysis with regards to Managing Director review comments.	2.1	\$ 534	\$ 1,121.40
Jess Commisso	06/10/20	(2.3) Continued, from earlier in the day, to update the PowerBI visuals per review comments received from I. Hirsch (KPMG Managing Director).	2.3	\$ 350	\$ 805.00
Isaac Hirsch	06/10/20	(0.6) Managing director review of potential Dutch pre-sale planning slides; (0.5) Managing Director review of potential Canadian pre-sale planning slides; (1.5) Managing Director review of valuation sensitivity analysis, in preparation for external call with Purdue and UCC legal and financial counsel.	2.6	\$ 819	\$ 2,129.40
Pete DiMatteo	06/10/20	International tax manager preparation of PowerPoint slides depicting proposed planning related to contemplated Canadian (2.4) and Dutch (1.4) dispositions.	3.8	\$ 650	\$ 2,470.00
Jess Commisso	06/10/20	(3.9) Updates to PowerBI visuals with regards to review comments received from I. Hirsch (KPMG Managing Director) as of 6/10/2020.	3.9	\$ 350	\$ 1,365.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Ashley Armfield	06/11/20	(0.5) Conference call between D. Holland (KPMG WNT), C. Nunez, I. Hirsch, P. DiMatteo, A. Armfield, and D. Rowles (KPMG) to discuss updates made to the Purdue cash tax model sensitivity analysis in preparation for external call with advisors.	0.5	\$ 534	\$ 267.00
Devon Rowles	06/11/20	(0.5) Conference call between D. Holland (KPMG WNT), C. Nunez, I. Hirsch, P. DiMatteo, A. Armfield, and D. Rowles (KPMG) to discuss updates made to the Purdue cash tax model sensitivity analysis in preparation for external call with advisors.	0.5	\$ 350	\$ 175.00
Douglas Holland	06/11/20	(0.5) Conference call between D. Holland (KPMG WNT), C. Nunez, I. Hirsch, P. DiMatteo, A. Armfield, and D. Rowles (KPMG) to discuss updates made to the Purdue cash tax model sensitivity analysis in preparation for external call with advisors.	0.5	\$ 985	\$ 492.50
Casey Nunez	06/11/20	(0.5) Conference call between D. Holland (KPMG WNT), C. Nunez, I. Hirsch, P. DiMatteo, A. Armfield, and D. Rowles (KPMG) to discuss updates made to the Purdue cash tax model sensitivity analysis in preparation for external call with advisors.	0.5	\$ 744	\$ 372.00
Isaac Hirsch	06/11/20	(0.5) Conference call between D. Holland (KPMG WNT), C. Nunez, I. Hirsch, P. DiMatteo, A. Armfield, and D. Rowles (KPMG) to discuss updates made to the Purdue cash tax model sensitivity analysis in preparation for external call with advisors.	0.5	\$ 819	\$ 409.50
Pete DiMatteo	06/11/20	(0.5) Conference call between D. Holland (KPMG WNT), C. Nunez, I. Hirsch, P. DiMatteo, A. Armfield, and D. Rowles (KPMG) to discuss updates made to the Purdue cash tax model sensitivity analysis in preparation for external call with advisors.	0.5	\$ 650	\$ 325.00
Casey Nunez	06/11/20	(0.8) Performed M&A Tax Senior Manager review of updates to global cash tax model as of 6/11/2020.	0.8	\$ 744	\$ 595.20
Alejandro Merelles Rodriguez	06/11/20	(0.8) Perform Senior Associate level review of the latest slide deck provided by the U.S. team regarding potential Mundipharma Disposition Analysis from Luxembourg tax perspective.	0.8	\$ 640	\$ 512.00
Sara Gonzalez Perez	06/11/20	(0.8) Perform Associate level review of the latest slide deck provided by the U.S. team regarding potential Mundipharma Disposition Analysis from Luxembourg tax perspective.	0.8	\$ 380	\$ 304.00
Jess Commisso	06/11/20	(1.2) Updates to the cash tax model to incorporate scenarios without certain deductions - per the client request.	1.2	\$ 350	\$ 420.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Lukas van der Veen	06/11/20	Review of Dutch tax comments included in deck on Mundipharma Disposition Analysis Potential Planning Opportunities as requested by P. DiMatteo (KPMG US).	1.3	\$ 565	\$ 734.50
Becky Holtje	06/11/20	(1.4) Perform research, as of 6/11/2020, to facilitate cash tax modeling relating to timing of certain deductions	1.4	\$ 744	\$ 1,041.60
Isaac Hirsch	06/11/20	Prepare for call with legal and financial advisors for Purdue and UCC by: preparing talking points for discussion (0.6); reviewing latest version of Purdue cash tax model (0.9); reviewing prior correspondence from Purdue and UCC legal and financial counsel (0.4).	1.9	\$ 819	\$ 1,556.10
Ashley Armfield	06/11/20	(3.2) Updating deliverable file with regards to Managing Director comments to be discussed on external call on 6/12/2020.	3.2	\$ 534	\$ 1,708.80
Isaac Hirsch	06/11/20	(1.6) Perform Managing Director review of valuation sensitivity analysis, in preparation for external call with Purdue and UCC legal and financial counsel; (1.9) performed Managing Director review of sensitivity analysis regarding allocation of proceeds between various entities, in preparation for external call with Purdue and UCC legal and financial counsel.	3.5	\$ 819	\$ 2,866.50
Sara Gonzalez Perez	06/11/20	Drafted high-level Luxembourg direct tax comments on the proposed dispositions depicted in the Dutch and Canadian Planning slide deck	3.7	\$ 380	\$ 1,406.00
Becky Holtje	06/11/20	(3.9) Continue (from previous day) to perform research to facilitate cash tax modeling relating to timing of certain deductions	3.9	\$ 744	\$ 2,901.60
Jess Commisso	06/11/20	(3.9) Updates to PowerBI visualizations of sensitivity analysis with regards to review comments received from A. Armfield (KPMG Senior associate).	3.9	\$ 350	\$ 1,365.00
Jess Commisso	06/11/20	(3.9) Updates to PowerBI visualizations of sensitivity analysis with regards to review comments received from I. Hirsch (KPMG Managing Director) as of 6/11/2020.	3.9	\$ 350	\$ 1,365.00
Becky Holtje	06/12/20	(0.2) Continue, same day, to perform research to facilitate cash tax modeling relating to timing of certain deductions	0.2	\$ 744	\$ 148.80
Casey Nunez	06/12/20	(0.5) Conference with C. Nunez, D. Holland, and I. Hirsch (KPMG) to discuss preparation for external call with legal and financial advisors for Purdue and the UCC regarding sources of foreign tax in the global cash tax model, sensitivity analysis around effect of changes in valuation on global cash tax liability, and sensitivity analysis around effect of allocation of proceeds on global cash tax liability	0.5	\$ 744	\$ 372.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Douglas Holland	06/12/20	(0.5) Conference with C. Nunez, D. Holland, and I. Hirsch (KPMG) to discuss preparation for external call with legal and financial advisors for Purdue and the UCC regarding sources of foreign tax in the global cash tax model, sensitivity analysis around effect of changes in valuation on global cash tax liability, and sensitivity analysis around effect of allocation of proceeds on global cash tax liability	0.5	\$ 985	\$ 492.50
Isaac Hirsch	06/12/20	(0.5) Conference with C. Nunez, D. Holland, and I. Hirsch (KPMG) to discuss preparation for external call with legal and financial advisors for Purdue and the UCC regarding sources of foreign tax in the global cash tax model, sensitivity analysis around effect of changes in valuation on global cash tax liability, and sensitivity analysis around effect of allocation of proceeds on global cash tax liability	0.5	\$ 819	\$ 409.50
Lukas van der Veen	06/12/20	(0.5) Finalize Manager level review comments included in deck on Mundipharma Disposition Analysis Potential Planning Opportunities (based on review of the deck with KPMG US) in preparation to send to P. DiMatteo (KPMG US).	0.5	\$ 565	\$ 282.50
Aroen Rambhadjan	06/12/20	Partner review of draft comments included in deck on Mundipharma Disposition Analysis Potential Planning Opportunities (based on review of the deck with KPMG US) and concurrently revised - as needed.	0.6	\$ 884	\$ 530.40
Becky Holtje	06/12/20	(1.0) Conference with H. Steinberg, M. Hoffenberg, C. Nunez, D. Holland, P. DiMatteo, B. Unell, R. Holtje, and I. Hirsch (KPMG) and various advisors for Purdue and UCC to discuss sources of foreign tax in the global cash tax model, sensitivity analysis around effect of changes in valuation on global cash tax liability, and sensitivity analysis around effect of allocation of proceeds on global cash tax liability	1.0	\$ 744	\$ 744.00
Bela Unell	06/12/20	(1.0) Conference with H. Steinberg, M. Hoffenberg, C. Nunez, D. Holland, P. DiMatteo, B. Unell, R. Holtje, and I. Hirsch (KPMG) and various advisors for Purdue and UCC to discuss sources of foreign tax in the global cash tax model, sensitivity analysis around effect of changes in valuation on global cash tax liability, and sensitivity analysis around effect of allocation of proceeds on global cash tax liability	1.0	\$ 744	\$ 744.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Casey Nunez	06/12/20	(1.0) Conference with H. Steinberg, M. Hoffenberg, C. Nunez, D. Holland, P. DiMatteo, B. Unell, R. Holtje, and I. Hirsch (KPMG) and various advisors for Purdue and UCC to discuss sources of foreign tax in the global cash tax model, sensitivity analysis around effect of changes in valuation on global cash tax liability, and sensitivity analysis around effect of allocation of proceeds on global cash tax liability	1.0	\$ 744	\$ 744.00
Douglas Holland	06/12/20	(1.0) Conference with H. Steinberg, M. Hoffenberg, C. Nunez, D. Holland, P. DiMatteo, B. Unell, R. Holtje, and I. Hirsch (KPMG) and various advisors for Purdue and UCC to discuss sources of foreign tax in the global cash tax model, sensitivity analysis around effect of changes in valuation on global cash tax liability, and sensitivity analysis around effect of allocation of proceeds on global cash tax liability	1.0	\$ 985	\$ 985.00
Howard Steinberg	06/12/20	(1.0) Conference with H. Steinberg, M. Hoffenberg, C. Nunez, D. Holland, P. DiMatteo, B. Unell, R. Holtje, and I. Hirsch (KPMG) and various advisors for Purdue and UCC to discuss sources of foreign tax in the global cash tax model, sensitivity analysis around effect of changes in valuation on global cash tax liability, and sensitivity analysis around effect of allocation of proceeds on global cash tax liability	1.0	\$ 856	\$ 856.00
Isaac Hirsch	06/12/20	(1.0) Conference with H. Steinberg, M. Hoffenberg, C. Nunez, D. Holland, P. DiMatteo, B. Unell, R. Holtje, and I. Hirsch (KPMG) and various advisors for Purdue and UCC to discuss sources of foreign tax in the global cash tax model, sensitivity analysis around effect of changes in valuation on global cash tax liability, and sensitivity analysis around effect of allocation of proceeds on global cash tax liability	1.0	\$ 819	\$ 819.00
Mark Hoffenberg	06/12/20	(1.0) Conference with H. Steinberg, M. Hoffenberg, C. Nunez, D. Holland, P. DiMatteo, B. Unell, R. Holtje, and I. Hirsch (KPMG) and various advisors for Purdue and UCC to discuss sources of foreign tax in the global cash tax model, sensitivity analysis around effect of changes in valuation on global cash tax liability, and sensitivity analysis around effect of allocation of proceeds on global cash tax liability	1.0	\$ 980	\$ 980.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Pete DiMatteo	06/12/20	(1.0) Conference with H. Steinberg, M. Hoffenberg, C. Nunez, D. Holland, P. DiMatteo, B. Unell, R. Holtje, and I. Hirsch (KPMG) and various advisors for Purdue and UCC to discuss sources of foreign tax in the global cash tax model, sensitivity analysis around effect of changes in valuation on global cash tax liability, and sensitivity analysis around effect of allocation of proceeds on global cash tax liability	1.0	\$ 650	\$ 650.00
Ashley Armfield	06/12/20	(1.1) Additional updates to client deliverable for sensitivity analysis in preparation for discussion (later today).	1.1	\$ 534	\$ 587.40
Paul Harden	06/12/20	Preparation of UK trust tax analysis in response to the query from KPMG US regarding UK tax implications of a potential transfer of proceeds from the proposed transaction ahead of their call with the client.	1.5	\$ 985	\$ 1,477.50
Paul Harden	06/12/20	(1.5) Continued, from same day, preparation of UK trust tax analysis in response to the query from KPMG US.	1.5	\$ 985	\$ 1,477.50
Isaac Hirsch	06/12/20	(0.8) Managing Director review of updated valuation sensitivity analysis, incorporating comments from the KPMG project team as of 6/12/2020; (1.1) Managing Director review of updated sensitivity concerning allocation of proceeds, incorporating comments from KPMG project team as of 6/12/2020.	1.9	\$ 819	\$ 1,556.10
Becky Holtje	06/12/20	$(3.9) \ Performed \ research, \ as \ of \ 6/12/2020, \ to \ facilitate \ cash \ tax \\ modeling \ relating \ to \ timing \ of \ certain \ deductions$	3.9	\$ 744	\$ 2,901.60
Fred van Horzen	06/15/20	Discussion with A. Rambhadjan (KPMG Netherlands), L. van der Veen (KPMG Netherlands) and F. van Horzen (KPMG Netherlands) - partial attendance on potential tax consequences related to disposition of a Dutch entity	0.2	\$ 884	\$ 176.80
Aroen Rambhadjan	06/15/20	Discussion with A. Rambhadjan (KPMG Netherlands), L. van der Veen (KPMG Netherlands) and F. van Horzen (KPMG Netherlands) - partial attendance on potential tax consequences related to disposition of a Dutch entity	0.5	\$ 884	\$ 442.00
Lukas van der Veen	06/15/20	Discussion with A. Rambhadjan (KPMG Netherlands), L. van der Veen (KPMG Netherlands) and F. van Horzen (KPMG Netherlands) - partial attendance on potential tax consequences related to disposition of a Dutch entity	0.5	\$ 565	\$ 282.50
Robin Lijzenga	06/15/20	Meeting with A. Merelles and S. Gonzalez (all KPMG) to discuss the additional dispositions depicted in the Dutch and Canadian Planning slide deck regarding the Mundipharma Disposition Analysis	0.5	\$ 730	\$ 365.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Sara Gonzalez Perez	06/15/20	Meeting with R. Lijzenga and A. Merelles (all KPMG) to discuss the additional dispositions depicted in the Dutch and Canadian Planning slide deck regarding the Mundipharma Disposition Analysis	0.5	\$ 380	\$ 190.00
Alejandro Merelles Rodriguez	06/15/20	Meeting with R. Lijzenga and S. Gonzalez (all KPMG) to discuss the additional dispositions depicted in the Dutch and Canadian Planning slide deck regarding the Mundipharma Disposition Analysis	0.5	\$ 640	\$ 320.00
Devon Rowles	06/15/20	(0.7) Updating the document listing tracker to include information received in the virtual data room (VDR) as of 6/15/2020.	0.7	\$ 350	\$ 245.00
Sara Gonzalez Perez	06/15/20	Continue (from 6/11) to draft high-level potential Luxembourg tax comments on the additional dispositions depicted in the Dutch and Canadian Planning slide deck regarding the Mundipharma Disposition Analysis	0.9	\$ 380	\$ 342.00
Isaac Hirsch	06/15/20	(1.1) Performed Managing Director review of updated cash tax summary prepared in response to follow-up request from UCC and Purdue legal and financial advisors	1.1	\$ 819	\$ 900.90
Becky Holtje	06/15/20	(1.5) Continue, on same day, to perform research to facilitate cash tax modeling regarding timing of certain deductions	1.5	\$ 744	\$ 1,116.00
Devon Rowles	06/15/20	(1.7) Reviewed the virtual data room for tax relevant information received as of 6/15/2020 in order to notify the wider KPMG US team about tax relevant documents received	1.7	\$ 350	\$ 595.00
Emilien Lebas	06/15/20	Performed Partner review and concurrently revised the draft high-level potential Luxembourg tax comments on the Dutch & Canadian Planning slide deck regarding the Mundipharma Disposition Analysis	2.2	\$ 985	\$ 2,167.00
Jess Commisso	06/15/20	(2.8) Creation of tax attribute table within the cash tax model based on various disposition scenarios pursuant to client request.	2.8	\$ 350	\$ 980.00
Robin Lijzenga	06/15/20	Manager review and concurrently revise the draft high-level potential Luxembourg tax comments on the Dutch & Canadian Planning slide deck regarding the Mundipharma Disposition Analysis	3.2	\$ 730	\$ 2,336.00
Alejandro Merelles Rodriguez	06/15/20	Performed Senior Associate level review and concurrently revised the draft high-level potential Luxembourg tax comments on the Dutch & Canadian Planning slide deck regarding the Mundipharma Disposition Analysis	3.4	\$ 640	\$ 2,176.00
Becky Holtje	06/15/20	(3.9) Performed research, as of 6/15/2020, to facilitate cash tax modeling relating to timing of certain deductions	3.9	\$ 744	\$ 2,901.60

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	06/15/20	(3.9) Updating the Purdue cash tax model for a summary depicting certain tax attributes.	3.9	\$ 350	\$ 1,365.00
Casey Nunez	06/16/20	(0.3) Correspondence with Province regarding potential tax deductions.	0.3	\$ 744	\$ 223.20
Emilien Lebas	06/16/20	Partner review of final draft of the Dutch & Canadian Planning slide deck regarding the Mundipharma Disposition Analysis, prior to providing to KPMG U.S. team.	0.8	\$ 985	\$ 788.00
Robin Lijzenga	06/16/20	Performed manager review and concurrently amend the first draft of the Dutch & Canadian Planning slide deck regarding the Mundipharma Disposition Analysis, with respect to updates related to Partner review comments.	0.8	\$ 730	\$ 584.00
Ashley Armfield	06/16/20	(0.9) Discussion with I. Hirsch, A. Armfield, D. Rowles and J. Commisso (KPMG) regarding updates to potential deductions' effect on the cash tax model as of 6/16/2020.	0.9	\$ 534	\$ 480.60
Devon Rowles	06/16/20	(0.9) Discussion with I. Hirsch, A. Armfield, D. Rowles and J. Commisso (KPMG) regarding updates to potential deductions' effect on the cash tax model as of 6/16/2020.	0.9	\$ 350	\$ 315.00
Isaac Hirsch	06/16/20	(0.9) Discussion with I. Hirsch, A. Armfield, D. Rowles and J. Commisso (KPMG) regarding updates to potential deductions' effect on the cash tax model as of 6/16/2020.	0.9	\$ 819	\$ 737.10
Jess Commisso	06/16/20	(0.9) Discussion with I. Hirsch, A. Armfield, D. Rowles and J. Commisso (KPMG) regarding updates to potential deductions' effect on the cash tax model as of 6/16/2020.	0.9	\$ 350	\$ 315.00
Jonas Lau	06/16/20	Canadian Senior Manager review of KPMG US slide deck with regards to incorporation of Canadian planning alternatives	0.9	\$ 614	\$ 552.60
Isaac Hirsch	06/16/20	(1.1) Managing Director review of additional updates to cash tax summary prepared in response to follow-up request from UCC and Purdue legal and financial advisors	1.1	\$ 819	\$ 900.90
Sara Gonzalez Perez	06/16/20	Updated first draft of the Dutch & Canadian Planning slide deck regarding the Mundipharma Disposition Analysis based on review comments resulting from Partner review.	1.1	\$ 380	\$ 418.00
Casey Nunez	06/16/20	(1.2) Performed M&A Tax Senior Manager review of updates to cash tax model, as of 6/16/2020, for additional sensitivity analyses.	1.2	\$ 744	\$ 892.80
Alejandro Merelles Rodriguez	06/16/20	Perform Senior Associate level review and concurrently revised first draft of the Dutch & Canadian Planning slide deck regarding the Mundipharma Disposition Analysis with specific regards to updates related to Partner review comments.	2.1	\$ 640	\$ 1,344.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	06/16/20	(2.4) Continue (from prior day) to update the Purdue cash tax model for a summary depicting certain tax attributes	2.4	\$ 350	\$ 840.00
Becky Holtje	06/16/20	(2.7) Perform research, as of 6/16/2020, to facilitate cash tax modeling relating to timing of certain deductions	2.7	\$ 744	\$ 2,008.80
Jess Commisso	06/17/20	(1.1) Updates to the cash tax model with regards to sensitivity analysis requests from the client.	1.1	\$ 350	\$ 385.00
Isaac Hirsch	06/17/20	(1.2) Managing Director review of additional updates to cash tax summary prepared in response to follow-up request from UCC and Purdue legal and financial advisors	1.2	\$ 819	\$ 982.80
Devon Rowles	06/17/20	(1.8) Update the Purdue cash tax model per review comments received from I. Hirsch (KPMG Managing Director) as of 6/17/2020 regarding certain potential deductions	1.8	\$ 350	\$ 630.00
Devon Rowles	06/17/20	(1.9) Updated the Purdue cash tax model per review comments received from I. Hirsch (KPMG Managing Director) as of 6/17/2020	1.9	\$ 350	\$ 665.00
Frankie Angeleri	06/18/20	(2.3) Associate preparation of summary of all entities functions in order to analyze the transfer policy	2.3	\$ 520	\$ 1,196.00
Molly Minnear	06/19/20	(0.2) Meeting with M. Minnear, K. Taylor and F. Angeleri (KPMG) to discuss next steps with regard to beginning the transfer pricing analysis.	0.2	\$ 868	\$ 173.60
Frankie Angeleri	06/19/20	(0.2) Meeting with M. Minnear, K. Taylor and F. Angeleri (KPMG) to discuss next steps with regard to beginning the transfer pricing analysis.	0.2	\$ 520	\$ 104.00
Kieran Taylor	06/19/20	(0.2) Meeting with M. Minnear, K. Taylor and F. Angeleri (KPMG) to discuss next steps with regard to beginning the transfer pricing analysis.	0.2	\$ 744	\$ 148.80
Frankie Angeleri	06/19/20	(0.8) Creating functional analysis of the entities with the given information in order to gain insight into the transfer pricing structure and transfer pricing policies in place	0.8	\$ 520	\$ 416.00
Ashley Armfield	06/22/20	(1.1) Reviewing request received by external counsel relating to cash tax modeling and sensitivity analysis to determine next steps.	1.1	\$ 534	\$ 587.40
Pete DiMatteo	06/22/20	Performed international tax manager review and concurrently revised slide deck depicting potential Canadian (1.1) and Dutch planning (1.0).	2.1	\$ 650	\$ 1,365.00
Isaac Hirsch	06/22/20	(2.2) Perform managing director review of updated sensitivity analysis as of 6/22/2020.	2.1	\$ 819	\$ 1,719.90
Casey Nunez	06/22/20	(2.3) Performed M&A Tax Senior Manager review of additional cash tax modeling scenarios to respond to requests for further detail.	2.3	\$ 744	\$ 1,711.20
Frankie Angeleri	06/22/20	(2.5) Began to prepare transfer pricing analysis memo	2.5	\$ 520	\$ 1,300.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	06/22/20	(3.6) Revised assigned portion of the Purdue cash tax model based on review comments received from A. Armfield (KPMG) as of 6/22/2020.	3.6	\$ 350	\$ 1,260.00
Jess Commisso	06/23/20	(1.1) Updated the Purdue sensitivity analysis deliverables per review comments received from I. Hirsch (KPMG Managing Director) as of 6/23/2020.	1.1	\$ 350	\$ 385.00
Devon Rowles	06/23/20	(1.4) Updates to the Purdue cash tax model for per review comments received from C. Nunez (KPMG Senior Manager) as of 6/23/2020.	1.4	\$ 350	\$ 490.00
Devon Rowles	06/23/20	(2.8) Updates to the Purdue cash tax model for per review comments received from I. Hirsch (KPMG Managing Director) as of 6/23/2020.	2.8	\$ 350	\$ 980.00
Isaac Hirsch	06/23/20	(2.2) Performed a managing director review of updated sensitivity analysis as of 6/23/2020 while concurrently drafting review comments; (1.7) Performed managing director review of planning slides for Dutch structure as of 6/23/2020 and concurrently draft review comments.	3.9	\$ 819	\$ 3,194.10
Casey Nunez	06/23/20	(2.8) Perform M&A Tax Senior Manager review of 4 modeling scenarios; (1.2) Performed M&A Tax Senior Manager review of updated summary deliverables as of 6/23/2020.	4.0	\$ 744	\$ 2,976.00
Casey Nunez	06/24/20	(0.4) Perform M&A Tax Senior Manager review of updates to information request list to respond to client request related to material open items as of 6/24/2020.	0.4	\$ 744	\$ 297.60
Kieran Taylor	06/24/20	(1.2) Senior Manager review of transfer pricing analysis memo.	1.2	\$ 744	\$ 892.80
Frankie Angeleri	06/24/20	(3.0) Continue, from 6/22, to prepare transfer pricing analysis memo	3.0	\$ 520	\$ 1,560.00
Isaac Hirsch	06/24/20	(2.2) Performed managing director review of updated sensitivity analysis as of 6/24/2020; (1.5) continue from 6/23) to perform managing director review of planning slides for Dutch structure	3.7	\$ 819	\$ 3,030.30
Frankie Angeleri	06/25/20	Meeting with M. Minnear (KPMG), K. Taylor (KPMG) and F. Angeleri (KPMG) to discuss the preliminary draft and structure of KPMG's draft transfer pricing summary memo.	0.4	\$ 520	\$ 208.00
Molly Minnear	06/25/20	Meeting with M. Minnear (KPMG), K. Taylor (KPMG) and F. Angeleri (KPMG) to discuss the preliminary draft and structure of KPMG's draft transfer pricing summary memo.	0.4	\$ 868	\$ 347.20
Kieran Taylor	06/25/20	Meeting with M. Minnear (KPMG), K. Taylor (KPMG) and F. Angeleri (KPMG) to discuss the preliminary draft and structure of KPMG's draft transfer pricing summary memo.	0.4	\$ 744	\$ 297.60

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Jess Commisso	06/25/20	0.8 Updates to sensitivity analysis deliverables per review comments received from I. Hirsch (KPMG managing director).	0.8	\$ 350	\$ 280.00
Casey Nunez	06/25/20	(1.3) Performed M&A Tax Senior Manager review of updated 25-page deliverable summarizing numerous aspects of the global cash tax model.	1.3	\$ 744	\$ 967.20
Isaac Hirsch	06/25/20		3.7	\$ 819	\$ 3,030.30
Frankie Angeleri	06/25/20	3.7 Continued (from 6/22) to prepare transfer pricing analysis memo	3.7	\$ 520	\$ 1,924.00
Casey Nunez	06/26/20	(0.8) Discussion with Davis Polk & Wardwell LLP and Akin Gump Strauss Hauer & Field LLP teams and M. Hoffenberg, I. Hirsch, C. Nunez and J. Commisso (all KPMG) regarding critical outstanding items and next steps needed to satisfy current assumptions and further Mundipharma analysis.	0.8	\$ 744	\$ 595.20
Isaac Hirsch	06/26/20	(0.8) Discussion with Davis Polk & Wardwell LLP and Akin Gump Strauss Hauer & Field LLP teams and M. Hoffenberg, I. Hirsch, C. Nunez and J. Commisso (all KPMG) regarding critical outstanding items and next steps needed to satisfy current assumptions and further Mundipharma analysis.	0.8	\$ 819	\$ 655.20
Jess Commisso	06/26/20	(0.8) Discussion with Davis Polk & Wardwell LLP and Akin Gump Strauss Hauer & Field LLP teams and M. Hoffenberg, I. Hirsch, C. Nunez and J. Commisso (all KPMG) regarding critical outstanding items and next steps needed to satisfy current assumptions and further Mundipharma analysis.	0.8	\$ 350	\$ 280.00
Mark Hoffenberg	06/26/20	(0.8) Discussion with Davis Polk & Wardwell LLP and Akin Gump Strauss Hauer & Field LLP teams and M. Hoffenberg, I. Hirsch, C. Nunez and J. Commisso (all KPMG) regarding critical outstanding items and next steps needed to satisfy current assumptions and further Mundipharma analysis.	0.8	\$ 980	\$ 784.00
Casey Nunez	06/26/20	(0.9) Review of outstanding items in connection with cash tax modeling as of $6/26/2020$ - in preparation for upcoming call with client.	0.9	\$ 744	\$ 669.60
Isaac Hirsch	06/26/20	(0.3) Performed Managing director review of updated information request list as of 6/26/2020; (1.1) prepared for upcoming call with Purdue and UCC legal and financial advisors by reviewing most current version of the Purdue global cash tax model	1.4	\$ 819	\$ 1,146.60

19-23649-shl Doc 1548 Filed 08/05/20 Entered 08/05/20 12:43:21 Main Document Pg 25 of 32

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Jess Commisso	06/26/20	1.7 Review of documentation provided by client in virtual data room to indicate relevance to engagement and share with the rest of the internal KPMG tax team.	1.7	\$ 350	\$ 595.00
		Total Bankruptcy Tax Consulting Services	326.3		\$ 197,404.60

19-23649-shl Doc 1548 Filed 08/05/20 Entered 08/05/20 12:43:21 Main Document Pg 26 of 32

EXHIBIT C2

Purdue Pharma L.P. Case No. 19-23649

Non -Working Travel Time June 1, 2020 through June 30, 2020

Name	Date	Description	Hours	Rate	Amount	
		no fees billed for these services in current month				
		Total Non-Working Travel Time		•	\$ -	_

19-23649-shl Doc 1548 Filed 08/05/20 Entered 08/05/20 12:43:21 Main Document Pg 27 of 32

EXHIBIT C3

Purdue Pharma L.P.
Case No. 19-23649
Retention Services
June 1, 2020 through June 30, 2020

Name	Date	Description	Hours	Rate	Amount
	i	no fees billed for these services in current month			
		Total Retention Services	0.0		\$ -

Purdue Pharma L.P. Case No. 19-23649

Fee Application Preparation Services June 1, 2020 through June 30, 2020

Name	Date	Description	Hours	Rate	A	Mount
Wendy Shaffer	06/01/20	(0.1) Drafted email to H. Steinberg KPMG regarding approval of Purdue April monthly fee statement; (0.2) Finalized PDF Purdue April fee statement; (0.1) send copy of same to M Plangman KPMG to request approval of same; (0.1) send email to counsel to request filing services of Purdue April monthly fee statement	0.5	\$ 202	\$	101.00
Wendy Shaffer	06/02/20	(0.1) Prepare email to send copy of KPMG's 4th monthly fee statement to UST and Fee Examiner once it is approved by counsel	0.1	\$ 202	\$	20.20
Wendy Shaffer	06/03/20	(0.2) Reviewed email from M. Pera (David Polk) regarding updates requested to Purdue Pharma 4th monthly fee statement and forward to M. Plangman and C. Nunez (both KPMG) for review; (1.0) Updates to Purdue Pharma April monthly fee statement exhibits per direction from M. Pera (Davis Polk); (0.5) Incorporated updates to Purdue Pharma 4th monthly performed by M. Land (KPMG) based on feedback received from Davis Polk	1.7	\$ 202	\$	343.40
Monica Plangman	06/05/20	(0.1) Review email and documents regarding M. Pera's (Davis Polk) revisions in Purdue monthly fee statement	0.1	\$ 264	\$	26.40
Wendy Shaffer	06/05/20	(0.1) Additional updates to Purdue Pharma April fee statement per direction from M. Pera (Davis Polk); (0.1) PDF final version of same and send revised version to counsel for filing.	0.2	\$ 202	\$	40.40
Wendy Shaffer	06/08/20	(0.6) Updated exhibit C1 of Purdue Pharma 5th monthly fee statement to include data received from KPMG member firm professionals as of 6/8/2020.	0.6	\$ 202	\$	121.20
Wendy Shaffer	06/14/20	(0.2) Reviewed Work in Progress report to confirm billable hours for Purdue as of 6/14.	0.2	\$ 202	\$	40.40
Wendy Shaffer	06/14/20	(0.2) Updates to Exhibit A of Purdue monthly fee statement exhibits to include additional team members including titles and corresponding rates.	0.2	\$ 202	\$	40.40
Wendy Shaffer	06/14/20	(0.2) Updates to Purdue May monthly fee statement to include data received from professionals as of 6/14/2020.	0.2	\$ 202	\$	40.40
Wendy Shaffer	06/15/20	(0.2) Began to create exhibits to be included in Purdue Pharma 2nd Interim application - copies of previously filed fee statements within the Interim period.	0.2	\$ 202	\$	40.40
Wendy Shaffer	06/15/20	(0.3) Created Purdue April fee statement in Excel to send to fee examiner and (0.1) send to M. Plangman (KPMG) for review.	0.4	\$ 202	\$	80.80
Wendy Shaffer	06/15/20	(0.6) Updated Purdue June monthly fee statement to include data received from KPMG foreign professionals as of 6/15/2020;	0.6	\$ 202	\$	121.20
Wendy Shaffer	06/15/20	(0.1) Drafted email to T. Nobis (Fee Examiner from BK Legal) to provide copy of KPMG's 4th monthly fee statement for review; 1.7 Updated exhibit C1 of Purdue May monthly fee statement to include data received from professionals as of 6/15/2020.	1.8	\$ 202	\$	363.60
Wendy Shaffer	06/16/20	(0.1) Drafted email to T. Nobis (KPMG) regarding timing to receive initial report related to KPMG's 1st Interim fee application in Purdue matter.	0.1	\$ 202	\$	20.20

Purdue Pharma L.P. Case No. 19-23649

Fee Application Preparation Services June 1, 2020 through June 30, 2020

Name	Date	Description	Hours	Rate	A	Amount
Wendy Shaffer	06/16/20	(1.5) Reviewing Purdue Fee Examiner initial report and begin to create spreadsheet to respond to fee examiner comments.	1.5	\$ 202	\$	303.00
Monica Plangman	06/17/20	Call with C. Nunez, S. Carlin and W. Shaffer (KPMG) regarding Fee Examiner's report and responses/findings.	0.8	\$ 264	\$	211.20
Wendy Shaffer	06/17/20	(0.1) Drafted email to provide copy of Purdue Pharma 4th monthly fee statement to US Trustee.	0.1	\$ 202	\$	20.20
Wendy Shaffer	06/17/20	(0.2) Review of Purdue work in progress report for June 1 - June 15 to confirm billable US hours as of 6/17/2020.	0.2	\$ 202	\$	40.40
Wendy Shaffer	06/17/20	(3.3) Multiple calls and emails with M. Plangman, S. Carlin and C. Nunez (all KPMG) regarding Fee examiner comments related to Purdue Pharma 1st Interim including providing direction to B. Defliese (KPMG) regarding consolidation of meeting info and identifying time submitted by professionals in future fee apps and corresponding updates to spreadsheet - in preparation to send to Fee Examiner for call on Friday.	3.30	\$ 202	\$	666.60
Wendy Shaffer	06/17/20	(3.5) Updates to exhibit C1 of Purdue May monthly fee statement to include data received from professionals as of 6/17/2020.	3.5	\$ 202	\$	707.00
Teresa Williams	06/17/20	Updated assigned portion of exhibit C1 of Purdue Pharma's 6th Monthly fee statement to include data received from professionals as of 6/17/20.	3.5	\$ 140	\$	490.00
Wendy Shaffer	06/18/20	(0.1) Review email communication from C. Nunez (KPMG) regarding response from H. Steinberg (KPMG Partner) related to initial report from fee examiner; (0.3) prepared Purdue May file to send to M. Land (KPMG) to perform updates based on previous communication from Davis Polk	0.4	\$ 202	\$	80.80
Monica Plangman	06/18/20	In order to prepare for call with Fee Examiner, gather pertinent data including updating file and transmit to S. Carlin (KPMG) for tomorrow's call.	0.5	\$ 264	\$	132.00
Wendy Shaffer	06/18/20	(0.8) Updated exhibit C1 of Purdue May monthly fee statement to include data received from professionals as of 6/18/2020.	0.8	\$ 202	\$	161.60
Monica Plangman	06/19/20	0.6 Continue to review responses/findings and update file; 0.1 transmit file to S. Carlin; 0.5 call with S. Carlin and Fee Examiner to review first monthly fee statement and report.	1.2	\$ 264	\$	316.80
Wendy Shaffer	06/21/20	Updates to Purdue May monthly per M. Land (KPMG) (0.3) and updates to same to include data received from professionals as of 6/21/2020 (1.1)	1.4	\$ 202	\$	282.80
Wendy Shaffer	06/22/20	0.1 Review of Proposed Order related to Purdue 1st Interim application including reductions from fee examiner and 0.1 draft response to M. Pera (Davis Polk) regarding approval of same.	0.2	\$ 202	\$	40.40
Wendy Shaffer	06/23/20	0.1 Drafted email to C. Nunez (KPMG) regarding status of Purdue May monthly fee statement and next steps to finalization.	0.5	\$ 202	\$	101.00
Monica Plangman	06/24/20	Associate director review of May fee statement and concurrently provide comments.	2.2	\$ 264	\$	580.80

Purdue Pharma L.P. Case No. 19-23649

Fee Application Preparation Services June 1, 2020 through June 30, 2020

Name	Date	Description	Hours	Rate	Amount
Wendy Shaffer	06/25/20	0.1 Review and respond to email from C. MacDonald (Purdue) regarding request for information related to KPMG 3rd and 4th monthly fee statements; 1.6 Updates to Purdue monthly exhibits per M. Plangman (KPMG) and 0.1 send to team for review approval.	1.8	\$ 202	\$ 363.60
Teresa Williams	06/25/20	Updated assigned portion of exhibit C1 of Purdue Pharma's 6th Monthly fee statement to include data received from professionals as of 6/25/20.	2.1	\$ 140	\$ 294.00
Teresa Williams	06/26/20	(0.7) Updated assigned portion of exhibit C1 of Purdue Pharma's 6th Monthly fee statement to include data received from professionals as of 6/26/20.	0.7	\$ 140	\$ 98.00
Wendy Shaffer	06/26/20	0.6 Finalized Updates to Purdue 5th monthly fee statement in preparation for Partner review; 0.1 drafted email to H. Steinberg (KPMG) to request approval / permission to apply signature of Purdue Pharma 5th monthly fee statement documents;	0.7	\$ 202	\$ 141.40
Monica Plangman	06/29/20	Associate director approval of fee statement prior to approval.	0.1	\$ 264	\$ 26.40
Wendy Shaffer	06/29/20	0.1 Drafted email to D. Consla (Davis Polk) to request filing and service of KPMG's 5th monthly fee statement in the Purdue Pharma bankruptcy matter; 0.2 Finalized (PDF) Purdue Pharma 5th monthly fee statement and 0.1 draft email to M. Plangman KPMG) to provide copy of same for final approval prior to filing: 0.4 Updated exhibit C1 of Purdue to include data received from professionals as of 6/29.	0.8	\$ 202	\$ 161.60
Wendy Shaffer	06/30/20	0.1 Final updates to Purdue May fee statement and send to M. Pera (Davis Polk) for filing.	0.1	\$ 202	\$ 20.20
		Total Fee Application Preparation Services	33.3		\$ 6,639.80

EXHIBIT D

Purdue Pharma L.P. Case No. 19-23649

Summary of Out of Pocket Expenses June 1, 2020 through June 30, 2020

Category	An	nount
Airfare	\$	-
Lodging	\$	-
Meals	\$	-
Ground Transportation	\$	-
Miscellaneous	\$	
Total	\$	-

19-23649-shl Doc 1548 Filed 08/05/20 Entered 08/05/20 12:43:21 Main Document Pg 32 of 32

EXHIBIT D1

Purdue Pharma L.P. Case No. 19-23649

Detail of Out of Pocket Expenses June 1, 2020 through June 30, 2020

Name	Date	Description	Amount
		Air Fare Subtotal	\$ -
		Lodging Subtotal	\$ -
		Meals Subtotal	\$ -
		Total Ground Transportation	\$ -
		Miscellaneous Subtotal	\$ -
		Total Out of Pocket Expenses	\$ -